213 related articles for article (PubMed ID: 32324926)
1. Investigating the presence of doubly phosphorylated α-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases.
Fayyad M; Erskine D; Majbour NK; Vaikath NN; Ghanem SS; Sudhakaran IP; Abdesselem H; Lamprokostopoulou A; Vekrellis K; Morris CM; Attems J; El-Agnaf OMA
Brain Pathol; 2020 Jul; 30(4):831-843. PubMed ID: 32324926
[TBL] [Abstract][Full Text] [Related]
2. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
[TBL] [Abstract][Full Text] [Related]
5. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
Walker DG; Lue LF; Adler CH; Shill HA; Caviness JN; Sabbagh MN; Akiyama H; Serrano GE; Sue LI; Beach TG;
Exp Neurol; 2013 Feb; 240():190-204. PubMed ID: 23201181
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine 136 phosphorylation of α-synuclein aggregates in the Lewy body dementia brain: involvement of serine 129 phosphorylation by casein kinase 2.
Sano K; Iwasaki Y; Yamashita Y; Irie K; Hosokawa M; Satoh K; Mishima K
Acta Neuropathol Commun; 2021 Nov; 9(1):182. PubMed ID: 34772466
[TBL] [Abstract][Full Text] [Related]
7. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
Oueslati A
J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
[TBL] [Abstract][Full Text] [Related]
9. Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event.
Kosten J; Binolfi A; Stuiver M; Verzini S; Theillet FX; Bekei B; van Rossum M; Selenko P
ACS Chem Neurosci; 2014 Dec; 5(12):1203-8. PubMed ID: 25320964
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders.
Lu Y; Prudent M; Fauvet B; Lashuel HA; Girault HH
ACS Chem Neurosci; 2011 Nov; 2(11):667-75. PubMed ID: 22860160
[TBL] [Abstract][Full Text] [Related]
12. Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson's Disease and Multiple System Atrophy.
Sonustun B; Altay MF; Strand C; Ebanks K; Hondhamuni G; Warner TT; Lashuel HA; Bandopadhyay R
Cells; 2022 Mar; 11(5):. PubMed ID: 35269528
[TBL] [Abstract][Full Text] [Related]
13. Exploring the role of post-translational modifications in regulating α-synuclein interactions by studying the effects of phosphorylation on nanobody binding.
El Turk F; De Genst E; Guilliams T; Fauvet B; Hejjaoui M; Di Trani J; Chiki A; Mittermaier A; Vendruscolo M; Lashuel HA; Dobson CM
Protein Sci; 2018 Jul; 27(7):1262-1274. PubMed ID: 29603451
[TBL] [Abstract][Full Text] [Related]
14. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
[TBL] [Abstract][Full Text] [Related]
15. Behavioral Deficits and Brain α-Synuclein and Phosphorylated Serine-129 α-Synuclein in Male and Female Mice Overexpressing Human α-Synuclein.
Gabrielyan L; Liang H; Minalyan A; Hatami A; John V; Wang L
J Alzheimers Dis; 2021; 79(2):875-893. PubMed ID: 33361597
[TBL] [Abstract][Full Text] [Related]
16. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
[TBL] [Abstract][Full Text] [Related]
17. Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia.
van der Gaag BL; Deshayes NAC; Breve JJP; Bol JGJM; Jonker AJ; Hoozemans JJM; Courade JP; van de Berg WDJ
Acta Neuropathol; 2024 Jan; 147(1):14. PubMed ID: 38198008
[TBL] [Abstract][Full Text] [Related]
18. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.
Landeck N; Hall H; Ardah MT; Majbour NK; El-Agnaf OM; Halliday G; Kirik D
Mol Neurodegener; 2016 Aug; 11(1):61. PubMed ID: 27549140
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.
Anderson JP; Walker DE; Goldstein JM; de Laat R; Banducci K; Caccavello RJ; Barbour R; Huang J; Kling K; Lee M; Diep L; Keim PS; Shen X; Chataway T; Schlossmacher MG; Seubert P; Schenk D; Sinha S; Gai WP; Chilcote TJ
J Biol Chem; 2006 Oct; 281(40):29739-52. PubMed ID: 16847063
[TBL] [Abstract][Full Text] [Related]
20. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
